目的 探讨金水宝胶囊联合沙美特罗替卡松粉吸入剂在支气管哮喘患者中的临床应用效果.方法 选取2012年6月-2014年6月收治的支气管哮喘患者96例,随机分为观察组和对照组.观察组给予金水宝胶囊联合沙美特罗替卡松粉吸入剂的药物治疗,而对照组则仅给予沙美特罗替卡松粉吸入剂的药物治疗,并分别比较和分析两组患者的临床治疗情况.结果 与对照组比较,观察组治愈率45.83%,总有效率95.83%均提高,而无效率4.17%降低,差异有统计学意义(χ2=4.554、5.031和5.031,p<0.05);与本组治疗前比较,两组治疗后肺功能指标水平均好转,差异有统计学意义(t=26.903、16.300、14.562、10.659、8.023和4.010,p<0.05);与对照组比较,观察经治疗后FVC(3.13±0.19)L、FEV1(2.79±0.50)L、PEF(4.87±0.92)L/S水平均提高,差异有统计学意义(t=6.435、4.181和4.038,p<0.05);与本组治疗前比较,两组治疗后细胞免疫因子水平均改善,差异有统计学意义(t=7.440、4.597、21.811、17.374、14.613和8.238,p<0.05).与对照组比较,观察经治疗后IL-17(0.45±0.23)ng/L和IL-4(7.85±1.89)ng/L水平均减少,而INF-γ(43.45±4.68)ng/L水平则增高,差异有统计学意义(t=4.191、5.106和6.229,p<0.05).结论 金水宝胶囊与沙美特罗替卡松粉吸入剂的药物联合治疗方案能够积极促进支气管哮喘患者整体疗效的提升,有效恢复患者肺功能,显著增强患者免疫功能,适宜作为支气管哮喘患者的理想治疗方案予以进一步的应用和推广.%Objective To probe into the clinical application effect of Jinshuibao capsules combined with Salmeterol Fluticasone Propionate Powder inhalation for patients with bronchial asthma. Methods From June 2012 to June 2014, 96 patients with bronchial asthma were selected. They were randomly divided into observation group and control group. The patients in the observation group were treated by Jinshuibao capsules and Salmeterol Fluticasone Propionate Powder inhalation. The patients in the control group were only treated with Salmeterol Fluticasone Propionate Powder inhalation. The clinical treatment indexes in the patients of the two groups were compared and analyzed. Results Compared with the control group, the curative rate (45.83%) and total effective rate (95.83%) in the observation group were significantly increased, while the inefficiency rate (4.17%) was significantly decreased (X2 = 4.554, 5.031 and 5.031; p< 0.05). The pulmonary function indicators were significantly improved after treatment in both groups compared with those before treatment (p < 0.05). Compared with the control group, the levels of FVC, FEV1 and PEF after treatment were significantly increased in the observation group ( t= 6.435, 4.181 and 4.038 respectively;p < 0.05). Compared with before treatment, the inflammatory cytokine levels were significantly improved after treatment in both groups ( p<0.05). Compared with the control group, IL-17 and IL-4 in the observation group were decreased significantly, and INF-γ was increased significantly ( t= 4.191, 5.106 and 6.229;p < 0.05). Conclusions Drug combination regimen of Jinshuibao capsules with Salmeterol Fluticasone Propionate Powder inhalation could actively improve the overall efficacy, promote recovery of pulmonary function, and significantly enhance immune function in patients with bronchial asthma. It is suitable to be used as an ideal treatment regimen for patients with bronchial asthma and to be of further application and promotion.
展开▼
